Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference

FOSTER CITY, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will be presenting at the H. C. Wainwright 6th Annual NASH Investor Conference on Monday, October 17 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days followingthe presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-ß agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
[email protected]

Media
Jenna Urban
Berry & Company Public Relations
[email protected]

[ Back To TMCnet.com's Homepage ]